Pacira BioSciences Sets the Record Straight Regarding DOMA’s Misleading Statements About Pacira’s Intellectual Property Strategy
Pacira BioSciences issued a statement urging stockholders to vote for its board nominees and disregard proxy materials from activist investor DOMA Perpetual Capital Management. The company defended its intellectual property strategy, highlighting that its EXPAREL franchise is protected by 21 Orange Book-listed patents across two families, with the newer '940 patent family providing exclusivity through July 2044.
Key figures
- Patent count
- 21
- Exclusivity end
- early 2030
- Market entry cap
- 2039
- Patent expiry 940
- July 2044
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.